U.S. Rx-to-OTC Switch Progression
Infographic representing the U.S. Rx-to-OTC Switch Progression. Download the file here or copy paste the link: http://bit.ly/1cQBmWw
JOIN OUR TEAM
Infographic representing the U.S. Rx-to-OTC Switch Progression. Download the file here or copy paste the link: http://bit.ly/1cQBmWw
There have been signs recently indicating that the environment is becoming ripe for more Rx-to-OTC switches. Since we last reported on this topic in August 2013, we saw the approval of two additional first-in-class switches in categories that would have been thought of as challenging five years ago. One is the first incontinence medication available
With a compound annual growth rate (CAGR) of 5.1% over the last three years, manufacturers’ sales of professional oral care products in the United States are offering much to smile about with sales in 2013 alone estimated at $426.5 million, according to Professional Oral Care USA, which includes extensive research with dentists and dental hygienists
With over half a century of market insights on the U.S. consumer healthcare market, Kline & Company expects that new paradigm shifts in regulations, retail, and technology will create new opportunities for medications to move along the Rx-to-OTC continuum and more growth prospects for the U.S. OTC market. Additionally, with the OTC medication market in
In the not so distant past, the U.S. FDA has taken a rather conservative stance concerning Rx-to-OTC switches. Many potential categories have been discounted as not safe and/or effective without a physician’s prescription. This has compelled drug manufacturers to judiciously consider which drugs, if any, they would seek to switch given the necessary multi-million dollar
With brick-and-mortar stores and online retailers already heavily competing for the consumer dollar in nearly all segments, OTC drug marketers should also be poised to take advantage of expanding sales and markets through both traditional channels and e-channels. The lines between these channels are blurring as online OTC drug retailers are offering brick-and-mortar store pickup,
The overall OTC market has not shown much excitement as of late, especially with low to no growth, manufacturing plant shut downs and brand recalls. However, in the nutritional products segment of the market, there is rapid growth and excitement and there have been several high profile acquisitions in this space recently showing that many
Given that many of the most obvious “switchable” drugs and categories have already taken place, opportunities that remain in moving medicines from prescription to nonprescription status require extensive research and novel approaches in order to gain FDA approval and be used by consumers safely and effectively without a prescription. There are several opportunities for new
As 2012 comes to a close, the U.S. OTC market shows signs of modest growth and recovery. Several companies that were once small in size have grown to become medium to large players, mainly from acquisitions of groups of brands. The largest firms have become leaner and streamlined their brand portfolios.
Rx-to-OTC switch brands continue to be major game changers on the OTC market, whether promoting strong gains or causing steep declines. Traditional OTC lines are delivering growth as they have expanded to meet consumer needs with the Centrum (Pfizer) and One-A-Day (Bayer) vitamin lines. Both of these lines using broad reaching marketing campaigns have had success with new product launches.
Cookie | Duration | Description |
---|---|---|
cookielawinfo-checkbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
cookielawinfo-checkbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
cookielawinfo-checkbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |